Salk Institute Inks Regenerative Medicine Research Pact with Sanofi-Aventis

The deal is Salk's second broad-based research pact with a drug maker in as many years: In early 2008 the non-profit biological research institute signed a similar deal in the area of inflammation with French specialty pharma Ipsen.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.